Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in <i>ROS1</i> Fusion–Positive Lung Cancer
Justin F. Gainor(Massachusetts General Hospital), Christina J. Falcon(Memorial Sloan Kettering Cancer Center), Jennifer Peterson(Harvard University), Jennifer S. Temel(Harvard University), Adam J. Schoenfeld(Memorial Sloan Kettering Cancer Center), Noura J. Choudhury(Memorial Sloan Kettering Cancer Center), Adam Langenbucher(Harvard University), Ted W. Johnson(WorldFish), Ibiayi Dagogo‐Jack(Massachusetts General Hospital), Satoshi Yoda(Harvard University), Subba R. Digumarthy(Massachusetts General Hospital), Ramin Sakhtemani(Harvard University), Alexander Drilon(Memorial Sloan Kettering Cancer Center), Harper Hubbeling(Memorial Sloan Kettering Cancer Center), Jochen K. Lennerz(Massachusetts General Hospital), Andrew Do(Harvard University), Michael S. Lawrence(Broad Institute), Lecia V. Sequist(Taipei Veterans General Hospital), Alice T. Shaw(Massachusetts General Hospital), Viola W. Zhu(University of California, Irvine), Aaron N. Hata(Harvard University), Sai‐Hong Ignatius Ou(University of California, Irvine Medical Center), Wafa Malik(Harvard University), Charlotte Lee(Harvard University), Kylie Prutisto-Chang(Harvard University), Beow Y. Yeap(Harvard University)
Cited by 137
Related Papers
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k